Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial
about
Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccinesA review of malaria vaccine clinical projects based on the WHO rainbow tableA phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720The Leeuwenhoek lecture 2006. Microscopy goes cold: frozen viruses reveal their structural secrets.Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines.Subviral particle as vaccine and vaccine platform.Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.Regulation of CD8+ T cell responses to infection with parasitic protozoa.Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.A review of adjuvants for Leishmania vaccine candidates.Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteinsBacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in miceA nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria.Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity.Virus-like particles: flexible platforms for vaccine development.Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy.Toll-like receptor 7 mediates early innate immune responses to malaria.Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms.Use of hepadnavirus core proteins as vaccine platforms.Virus-like particles in vaccine development.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions.Hepatitis B core-based virus-like particles to present heterologous epitopes.Subcutaneous immunization against Leishmania major - infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants.Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma.Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies.Tropical medicine at the University of Tübingen.
P2860
Q21032495-7B2F1A02-7CA9-4D21-AA27-5B3DCB1AE88BQ21034112-4D30E4A3-15DE-485C-9A9E-BAC4B0094D6DQ28744696-5CB715A1-DE19-4302-9F53-6BFC23498941Q33293785-26D5E764-3182-4CAD-A2D1-8BEDAF181EE0Q33318466-4A69A709-BD95-4E92-8846-2310CED2E46EQ33762869-B0D8F22F-FF98-4218-A5B6-F2B05316D28AQ33812439-B9BABF30-8914-41F7-940C-2876749F5B20Q33812653-DB77C6BA-D5C5-4F18-8630-1C75F3A90D9EQ33890011-4271838E-A9A6-4032-967A-2A409F714193Q34108177-03C503DC-8A01-4DDC-BD3E-B944AE036802Q34274515-C5495C3C-3A89-421B-94BA-24EBCA71D87CQ34546220-6B10C59F-758A-4A9F-BBFD-2E4F351FA189Q34647684-8C5E04DA-C84C-4E52-AE07-4EE32CB1983FQ34951967-B378F0AB-A9AD-41AD-9228-AC9676D611D8Q35191980-9120DE0B-7A71-466E-BEF0-94D202D79739Q35557657-BCE068D1-C835-4F8F-B056-19CF42482ADAQ35591846-41F33199-74A9-4AFF-B711-505D42D1DC27Q35914430-0EDF8144-7AE8-45A2-B809-B52334F43B27Q35927866-B0266B14-CA43-480A-AF71-25B717D87481Q36114395-02FF87AE-FAE8-4037-B7FF-A1287F0621D7Q36313990-D3BDEBA8-FCF5-44A6-B98C-B5E372F59149Q36383811-FB249D33-D8C7-42EC-AC83-C2EB0B850EFCQ36680084-60CBD62A-164A-46CD-AE12-6B6466A6E7F2Q36728808-03110036-561E-49B3-B800-1F560A2BEB43Q36837144-2263E227-9FAA-4581-A06C-FF6E08897018Q37036065-90B1D35F-F573-443C-86D2-C577BDFCF057Q37336051-97BEB2AD-604D-4513-8B20-A80073A17195Q37547757-AD6D8E47-6F25-47AB-AEDD-24E7565DEA32Q37622906-A4F4E14E-E172-407F-8638-234C2EE3B673Q37798008-178A4115-E516-4752-B0DD-AE5BC90BF764Q37812128-B2DF301A-306E-4570-993B-7937A03C42F6Q37873932-C8607496-AA8A-419D-BBC8-9EAC00D5E017Q37951525-C42AAE68-0C30-46D9-8322-E8F017184A4DQ37965724-D07252BD-196D-4D76-8A5D-22A37E97D778Q38059751-C6CCB195-3C7B-4CC7-903E-2B43A358D833Q38081969-006E61E3-0575-4DF2-922B-ADBE04FF4199Q39284820-C15CFB3D-8C19-4E6C-B1E4-5B5451181DFDQ39885468-9F6CD856-3112-4714-B70B-DCD6662F7C74Q41828356-AD96EAE8-8821-4E9B-9A9E-DC858D1B497EQ47938411-9421D12D-F489-4FF5-97F2-916F7D498636
P2860
Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@en
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@nl
type
label
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@en
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@nl
prefLabel
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@en
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@nl
P2093
P2860
P50
P921
P1476
Safety and enhanced immunogeni ...... ide ISA 720 in a phase I trial
@en
P2093
Adrian J F Luty
Annette Schmidt
Ashley Birkett
Christoph H Gleiter
Elizabeth H Nardin
Eveline Tierney
Filip Dubovsky
Gabriele Boehmer
Giane A Oliveira
J Mauricio Calvo-Calle
P2860
P304
P356
10.1128/IAI.73.6.3587-3597.2005
P407
P577
2005-06-01T00:00:00Z